Clinical trials: Placebo Response
Allergy
Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets
We plan to determine changes in the immune system during the allergic response to grass pollen allergens. We have chosen a particular element of the immune response, the immunoglobulin G4 (IgG4) as an indicator.
- Trial name
- NCT00413556
- Testing
- ALK Grass tablet
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- ALK-Abelló A/S
Osteoporosis
A Study of LY2541546 in Women With Low Bone Mineral Density
The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546…
- Trial name
- NCT01144377
- Testing
- LY2541546
- Where
- 8 sites in United States, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Dose-response in Japanese patients with postmenopausal osteoporosis.
- Trial name
- NCT00238745
- Testing
- Bazedoxifene
- Volunteers
- 375 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Colitis, Ulcerative
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis.
- Trial name
- NCT04613518
- Testing
- BMS-986165
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- AC4115321 (NCT01372410)
- Testing
- GSK573719, Tiotropium
- Where
- 13 sites in United States
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
- Trial name
- NCT00148486
- Testing
- NS 2330
- Where
- 55 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Diverticulitis
Prevention of Recurrence of Diverticulitis
The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.
- Trial name
- PREVENT2 (NCT00545103)
- Testing
- SPD476, MMX™ mesalazine, 1.2g extended release tablet, SPD476, MMX™ mesalazine, 2.4g extended release tablet, SPD476, MMX™ mesalazine, 4.8g extended release tablet
- Where
- 131 sites in United States, Brazil and 8 more
- Volunteers
- 592 people
- Sponsor
- Shire
Heart Failure
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
- Trial name
- QUID-HF (NCT02780180)
- Testing
- QGC001
- Where
- 23 sites in Czechia, France and 6 more
- Volunteers
- 23 people
- Sponsor
- Quantum Genomics SA
Sepsis
Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice.
- Trial name
- NCT01416376
- Testing
- SRT2379
- Where
- Netherlands
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Nosocomial Infections, Sepsis
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing…
- Conditions
- Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
- Trial name
- NCT00113191
- Testing
- Veronate
- Where
- 93 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.
- Trial name
- NCT00993668
- Testing
- Certolizumab pegol
- Where
- 41 sites in United States
- Volunteers
- 224 people
- Sponsor
- UCB Pharma
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Infections, Rotavirus, Rotavirus Vaccines
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
This study will provide data on the immune response and safety of GSK Biologicals' HRV liquid vaccine when given along with the routine infant immunizations in Philippines.
- Trial name
- NCT00432380
- Testing
- Rotarix™
- Where
- Philippines
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
- Trial name
- STRIDE (NCT06025110)
- Testing
- TCD601
- Where
- 26 sites in Belgium, Italy and 3 more
- Volunteers
- 9 people
- Sponsor
- ITB-Med LLC
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with…
- Trial name
- SELECT - PsA 2 (NCT03104374)
- Testing
- Upadacitinib
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 642 people
- Sponsor
- AbbVie
Crohn's Disease
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
STA-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells.
- Trial name
- NCT00138840
- Testing
- STA-5326 mesylate
- Where
- 35 sites in United States, Canada
- Volunteers
- 282 people
- Sponsor
- Synta Pharmaceuticals Corp.
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium